SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.54, Iss.7, 2013-07, pp. : 1488-1499

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

International Journal of Oncology, Vol. 47, Iss. 3, 2015-01 ,pp. : 900-908

Spandidos Publications

Access to resources Recommend Favorite

Chronic Myeloid Leukemia: The Value of Tyrosine Kinase Inhibition

By Tariq I. Mughal John M. Goldman

American Journal of Cancer, Vol. 2, Iss. 5, 2003-01 ,pp. : 305-311

Adis International

Access to resources Recommend Favorite

Tyrosine kinase inhibition in acute myeloid leukemia

By Altman Jessica K. Szilard Amy K. Platanias Leonidas C.

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1351-1352

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 8, 2009-10 ,pp. : 853-863

Bentham Science Publishers

Access to resources Recommend Favorite

Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 3, 2014-09 ,pp. : 382-393

Bentham Science Publishers

Access to resources Recommend Favorite